Conference Reports for NATAP

Back

14th International HIV Drug Resistance Workshop June 7-11, 2005 Quebec City, Quebec, Canada     14th International HIV Drug Resistance Workshop Reported for NATAP by David Margolis, MD, University of North Carolina (07/6/05)   Kaletra-NFV (study 863): using 1 copy viral load test may predict viral outcomes (06/20/05)   Tenofovir & Nuke Resistance Mutations & Patterns (06/17/05)   Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations (06/14/05)   Virologic Response to Antiretroviral Therapy in the Setting of the K65R Mutation (06/14/05)   Emergence of Drug Resistance Mutations During Treatment Interruption in Patients with Undetectable Viral Loads (06/14/05)   Integrase Inhibitor in Phase II (06/13/05)   BILR 355: New NNRTI (06/13/05)   PL-100, New Protease Inhibitor (06/13/05)   Methamphetamine and Sildenafil (Viagra) use are Associated with High-Risk Sexual Behavior with HIV-uninfected Partners & Transmission of HIV Drug Resistance (06/13/05)   Resistance to UK-427,857 does not result in cross-resistance to other entry inhibitors (06/13/05)   GSK CCR5 '140' (06/13/05)   Schering CCR5 Drug: Resistant viruses showed cross-resistance to other CCR5 inhibitors (06/13/05)   Tipranavir: predicting viral response (06/13/05)   Reyataz parameters predicting outcomes (06/13/05)   9% of Patients with Multi-Drug Resistant HIV Died Within 2 Years (06/13/05)   Nevirapine Resistance in Mother-To-Child Transmission (06/13/05)   Host Genetics & HIV (06/13/05)